Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
Go back to Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 126.75 -1.25 (0.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.00 | 52 Week High | $118.49 | |||
| Open | $126.46 | 52 Week Low | $55.00 | |||
| Day High | $128.08 | P/E | N/A | |||
| Day Low | $126.04 | EPS | $-0.56 | |||
| Volume | 1,036,074 | |||||
